NASDAQ Composite ended the session with Moderna jumping 11.09% to $145.55 on Monday while nASDAQ Composite jumped 0.26% to $13,577.94.
Moderna today’s close was $145.55, 22.64% below its 52-week high of $178.50.
News about Moderna today
According to today’s article on MarketWatch, "The other two vaccines, developed by BioNTech SE /Pfizer Inc. and Moderna Inc. , are both mRNA-based vaccines that received emergency use authorization from the Food and Drug Administration in December. "
According to today’s article on Bloomberg Quint, "The good news is, the Pfizer-BioNTech and Moderna shots do seem to work well, as does the vaccine developed by AstraZeneca and Oxford, though perhaps not as well as those other two. ", "While those two efforts appear to have disappointed, we now know that at least two shots using the newer mRNA technology-from Pfizer Inc.-BioNTech SE and Moderna Inc. -have had much better success and are now at the forefront of the global vaccination effort. "
Moderna’s sales growth is 1989.6% for the present quarter and 19117.5% for the next. The company’s growth estimates for the ongoing quarter and the next is 18.9% and 660%, respectively.
Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.
Moderna’s last day, last week, and last month’s average volatility was a negative 1.50%, a positive 0.22%, and a negative 0.28%, respectively.
Moderna’s last day, last week, and last month’s high and low average amplitude percentage was 5.41%, 5.61%, and 7.99%, respectively.
Moderna’s Stock Yearly Top and Bottom Value
Moderna’s stock is valued at $145.55 at 16:29 EST, way below its 52-week high of $178.50 and way higher than its 52-week low of $17.91.
Moderna’s Moving Average
Moderna’s worth is way higher than its 50-day moving average of $130.81 and way higher than its 200-day moving average of $90.07.
Previous days news about Moderna
According to Bloomberg Quint on Friday, 22 January, "What’s more, the technology used to make both the Pfizer-BioNTech and Moderna vaccines, which targets the coronavirus’ spike protein, was developed by scientists supported by the U.S. National Institutes of Health long before the pandemic began."